Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-2 Macroglobulin for Knee Osteoarthritis Biomarkers
NCT03656575Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Nov 2017
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alpha-2-macroglobulin enriched plasma in osteoarthritis (OA) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Synovial fluid biomarker levels at 3 months. Started Nov 2017; status: completed.
02
Drugs
alpha-2-macroglobulin enriched plasma
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03656575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656575.